1. Academic Validation
  2. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

  • Science. 2006 Apr 7;312(5770):117-21. doi: 10.1126/science.1124287.
Jennifer P Habashi 1 Daniel P Judge Tammy M Holm Ronald D Cohn Bart L Loeys Timothy K Cooper Loretha Myers Erin C Klein Guosheng Liu Carla Calvi Megan Podowski Enid R Neptune Marc K Halushka Djahida Bedja Kathleen Gabrielson Daniel B Rifkin Luca Carta Francesco Ramirez David L Huso Harry C Dietz
Affiliations

Affiliation

  • 1 Howard Hughes Medical Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Abstract

Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor-beta (TGF-beta) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

Figures